Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway

被引:84
作者
Baldassarre, G
Fedele, M
Battista, S
Vecchione, A
Klein-Szanto, AJP
Santoro, M
Waldmann, TA
Azimi, N
Croce, CM
Fusco, A
机构
[1] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg, Ctr Endocrinol Oncol Sperimentale,CNR, I-80131 Naples, Italy
[2] Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[5] Univ Catanzaro, Fac Med & Chirurgia Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy
关键词
D O I
10.1073/pnas.141224998
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Rearrangements of the high mobility group protein I-C (HMGI-C) gene, consisting in the loss of the carboxyl-terminal tail, have been frequently detected in benign human tumors of mesenchymal origin. We have previously demonstrated that transgenic (TG) mice carrying a truncated HMGI-C construct (HMCI-C/T) exhibit a giant phenotype together with a predominantly abdominal/pelvic lipomatosis. Here, we report that HMGI-C/T TG mice develop natural killer (NK)-T/NK cell lymphomas starting from 12 months of age. We found an increased expression of IL-2 and IL-15 proteins and their receptors in these lymphomas, and we demonstrate that HMGI-C/T protein positively regulates their expression in vitro. Therefore, the HRGI-C/T-mediated chronic stimulation of the IL2/IL-15 pathway could be responsible for the onset of NK-T/NK cell lymphomas in HMCI-C/T TG mice.
引用
收藏
页码:7970 / 7975
页数:6
相关论文
共 40 条
[1]   Clonal proliferation and cytokine requirement of murine progenitors for natural killer cells [J].
Aiba, Y ;
Hirayama, F ;
Ogawa, M .
BLOOD, 1997, 89 (11) :4005-4012
[2]  
ASHAR HR, 1995, CELL, V82, P57
[3]   Viral activation of interleukin-15 (IL-15): Characterization of a virus-inducible element in the IL-15 promoter region [J].
Azimi, N ;
Tagaya, Y ;
Mariner, J ;
Waldmann, TA .
JOURNAL OF VIROLOGY, 2000, 74 (16) :7338-7348
[4]  
Battista S, 1999, CANCER RES, V59, P4793
[5]   Interleukin-15 protects from lethal apoptosis in vivo [J].
BulfonePaus, S ;
Ungureanu, D ;
Pohl, T ;
Lindner, G ;
Paus, R ;
Ruckert, R ;
Krause, H ;
Kunzendorf, U .
NATURE MEDICINE, 1997, 3 (10) :1124-1128
[6]   Potential role for interleukin-15 in the regulation of human natural killer cell survival [J].
Carson, WE ;
Fehniger, TA ;
Haldar, S ;
Eckhert, K ;
Lindemann, MJ ;
Lai, CF ;
Croce, CM ;
Baumann, H ;
Caligiuri, MA .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (05) :937-943
[7]   INTERLEUKIN (IL)-15 IS A NOVEL CYTOKINE THAT ACTIVATES HUMAN NATURAL-KILLER-CELLS VIA COMPONENTS OF THE IL-2 RECEPTOR [J].
CARSON, WE ;
GIRI, JG ;
LINDEMANN, MJ ;
LINETT, ML ;
AHDIEH, M ;
PAXTON, R ;
ANDERSON, D ;
EISENMANN, J ;
GRABSTEIN, K ;
CALIGIURI, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) :1395-1403
[8]   MULTIPLE CLOSELY-LINKED NFAT-OCTAMER AND HMG I(Y) BINDING-SITES ARE PART OF THE INTERLEUKIN-4 PROMOTER [J].
CHUVPILO, S ;
SCHOMBERG, C ;
GERWIG, R ;
HEINFLING, A ;
REEVES, R ;
GRUMMT, F ;
SERFLING, E .
NUCLEIC ACIDS RESEARCH, 1993, 21 (24) :5694-5704
[9]   Cytokines: Shared receptors, distinct functions [J].
DiSanto, JP .
CURRENT BIOLOGY, 1997, 7 (07) :R424-R426
[10]   Aggressive natural killer cell leukemia/lymphoma [J].
Dunkley, S ;
Gibson, J ;
Mackinlay, N ;
Joshua, D .
PATHOLOGY, 1998, 30 (02) :157-159